Michael Francis Gormley

US Patent:

20210115517, Apr 22, 2021

Filed:

Jan 30, 2020

Appl. No.:

16/776734

Inventors:

Michael Gormley - Spring House PA, US
Shibu Thomas - Spring House PA, US

International Classification:

C12Q 1/6886
A61K 31/4439
A61K 45/06

Abstract:

Provided are methods of treating prostate cancer in a human male comprising administration of apalutamide and androgen deprivation therapy to a human male having prostate cancer (e.g., nmCRPC) if a biological sample obtained from the human male is determined to have a specific molecular subtype of prostate cancer, a specific classifier score, or increased or decreased expression of a signature class. The molecular subtypes include luminal-like or basal-like molecular subtype. Also provided are methods of using molecular signatures and genomic classifier scores, such as four co-regulated signature classes, metastasis risk based on a genomic classifier score, or a combination thereof, as prognostic indicators of apalutamide and androgen deprivation therapy in human males having prostate cancer, for improved treatment benefit.

US Patent:

20200338057, Oct 29, 2020

Filed:

Jun 5, 2020

Appl. No.:

16/894731

Inventors:

- Beerse, BE
Michael Gormley - Spring House PA, US
Shibu Thomas - Spring House PA, US

International Classification:

A61K 31/4439
G01N 33/574
A61P 35/00

Abstract:

Provided are methods of treating prostate cancer in a human male comprising administration of apalutamide and androgen deprivation therapy to a human male having prostate cancer (e.g., nmCRPC) if a biological sample obtained from the human male is determined to have a specific molecular subtype of prostate cancer, a specific classifier score, or increased or decreased expression of a signature class. The molecular subtypes include luminal-like or basal-like molecular subtype. Also provided are methods of using molecular signatures and genomic classifier scores, such as four co-regulated signature classes, metastasis risk based on a genomic classifier score, or a combination thereof, as prognostic indicators of apalutamide and androgen deprivation therapy in human males having prostate cancer, for improved treatment benefit.

US Patent:

20160304962, Oct 20, 2016

Filed:

Mar 11, 2016

Appl. No.:

15/067716

Inventors:

- BEERSE, BE
Shibu Thomas - North Wales PA, US
Michael Gormley - Mount Laurel NJ, US
Yashoda Rajpurohit - Hillsborough NJ, US
Michael Schaffer - Fort Washington PA, US

International Classification:

C12Q 1/68

Abstract:

Provided are whole blood based mRNA biomarkers for predicting prostate cancer and methods of detecting the same. The disclosed mRNA markers and methods enable the identification/diagnosis of a patient with prostate cancer, identification of a patient with/prediction of high-risk prostate cancer, and treatment of a patient with prostate cancer. Also provided are gene chips comprising the disclosed whole blood based mRNA biomarkers.

US Patent:

20150322523, Nov 12, 2015

Filed:

May 12, 2015

Appl. No.:

14/710093

Inventors:

- Beerse, BE
Weimin Li - Norristown PA, US
Michael Gormley - Mount Laurel NJ, US
Jayaprakash Karkera - Germantown MD, US
Michael Schaffer - Fort Washington MD, US

International Classification:

C12Q 1/68
A61K 31/573
A61K 31/58

Abstract:

Provided herein are methods of predicting a likelihood of survival following treatment with AA and prednisone in a patient having CRPC.

Address:

7810 Lister St, Philadelphia, PA 19152

VIN:

2FMDK36C37BA78002

Make:

FORD

Model:

EDGE

Year:

2007